ArticleACS sensors2025
Drug-Checking with Molecularly Imprinted Polymers: Addressing Xylazine-Contaminated Fentanyl.
Article in ACS sensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Xylazine adulterated Fentanyl is considered one of the deadliest drug threats ever faced in the United States. However, due to the complexity of the illegal drug supply, xylazine detection in the frame of drug-checking (harm reduction) remains an unsolved challenge, one which has cost numerous lives across North America. In this work, we present two sensor platforms for detecting xylazine in drug-checking applications. Both platforms are based on molecularly imprinted polymers (MIPs) using vinyl phosphonic acid as the main monomer. By combining the MIPs with thermometric and colorimetric readouts, we achieved xylazine detection in a wide concentration range, relevant in real-world scenarios. First, the heat-transfer method (HTM) allowed xylazine detection in the low concentration range within 15 min per concentration, with a limit of detection (LoD) of 16.5 ng/mL (75 nM). Second, a dye displacement assay employing methylene blue provided rapid (<5 min), visible detection with an LoD > 76 μg/mL-five times lower than the average concentration reported for street samples. Additionally, the colorimetric sensor exhibited potential for detecting various unwanted xylazine analogues, which could potentially act as fentanyl adulterants in the future. Most importantly, the colorimetric sensor consistently detected xylazine in a highly complex, street-like fentanyl sample containing five common interferents. The synergy of the proposed sensors offers a promising alternative for centralized and on-site xylazine screening in harm reduction settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.